Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
The direct correlation between high circulating lipidic levels and the risk of suffering from atherosclerosis, together with the modification of different lipoproteic fractions in the development of this disease, has led us to study the characteristics of the hypolipemic effect of Plafibride. Experiments were carried out on a model of experimental arteriosclerosis in rats. The drug was administered at four dosage levels during induction of arteriosclerosis in order to establish a possible dose-effect relationship. Evaluation of the therapeutic activity was analyzed against the atherosclerotic control group. We found a marked hypolipemic activity and a strong increase in HDL-cholesterol, which reached normal levels. Consequently, Plafibride presents a profile of activity which can be considered suitable in the treatment of atherosclerosis.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002995:Clofibric Acid; C016894:plafibride; D002784:Cholesterol; D002994:Clofibrate